RDY | Dr. Reddy's Laboratories Limited Stock Overview

(Stock Exchange: NYSE)

Day's Range	15.35 - 15.55
52 Week Range	13.41 - 16.89
Beta	0.51
Implied Volatility	35.82%
IV Rank	67.81%
Day's Volume	1,559,189
Average Volume	1,032,392
Shares Outstanding	833,033,430
Market Cap	12,803,723,819
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2001-04-11

Valuation
Profitability
Growth
Health
P/E Ratio	19.71
Forward P/E Ratio	N/A
EPS	0.78
1YR Price Target	N/A
Dividend Yield	0.66%
Dividend Per Share	0.10
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	27,048
Country	India
Website	RDY

Headquartered in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included biosimilar drug launches in select emerging markets and has shifted toward injectables and more complex generic products. Geographically, the company's sales are well dispersed across North America, India, and other emerging markets.

RDY's peers: ALKS, ANIP, ASRT, COLL, EVO, KMDA, LNTH, PAHC, PCRX, PRGO, SSIC, ITCI, EGRX, PBH, SUPN, DCPH, SIGA, VTRS, ALVO, HLN, SAY

*Chart delayed

Analyzing fundamentals for RDY we got that it has average fundamentals where Valuation is considered to be fairly valued, Profitability is very wealthy, Growth is on medium level and Health is passable. For more detailed analysis please see RDY Fundamentals page.

Watching at RDY technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on RDY Technicals page.